Advertisement

Microvascular cerebral blood volume changes in aging APPswe/PS1dE9 AD mouse model: a voxel-wise approach

Abstract

Vascular disorders can either be cause or consequence in the pathophysiology of Alzheimer’s disease (AD). To comprehensively characterize the occurrence of vascular impairment in a double transgenic mouse model for AD (APPswe/PS1dE9) during aging, we developed a new method to obtain microvascular relative cerebral blood volume (rCBVmicro) maps from gradient echo MR imaging by histogram evaluation and we applied a voxel-wise approach to detect rCBVmicro changes. With this methodology the development of cerebral microvascular impairments can be described in vivo with 0.16 mm isotropic resolution for the whole mouse brain. At 8 months, impaired rCBVmicro appeared in some cortical regions and in the thalamus, which spreads over several sub-cortical areas and the hippocampus at 13 months. With a ROI-based approach, we further showed that hippocampal rCBVmicro in 13-month-old wild-type and APPswe/PS1dE9 mice correlates well with capillary density measured with immunohistochemical staining. However, no differences in capillary density were detected between genotypes. The rCBVmicro values showed no significant correlation with amyloid-β (Aβ) plaque deposition, Aβ at blood vessel walls and biochemically measured levels of Aβ1-40, Aβ1-42 oligomers and fibrillar forms. These results suggest that rCBVmicro reduction is caused by an impaired vasoactivity of capillaries and arterioles, which is not directly correlated with the amount of Aβ deposition in parenchyma nor blood vessel walls.

This is a preview of subscription content, log in to check access.

Access options

Buy single article

Instant unlimited access to the full article PDF.

US$ 39.95

Price includes VAT for USA

Subscribe to journal

Immediate online access to all issues from 2019. Subscription will auto renew annually.

US$ 199

This is the net price. Taxes to be calculated in checkout.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

References

  1. Altman R, Rutledge JC (2010) The vascular contribution to Alzheimer’s disease. Clin Sci (Lond) 119:407–421

  2. Ashburner J, Friston KJ (2000) Voxel-based morphometry—the methods. NeuroImage 11:805–821

  3. Avants BB, Epstein CL, Grossman M, Gee JC (2008) Symmetric diffeomorphic image registration with cross-correlation: evaluating automated labeling of elderly and neurodegenerative brain. Med Image Anal 12:26–41

  4. Beckmann N, Schuler A, Mueggler T, Meyer EP, Wiederhold KH, Staufenbiel M, Krucker T (2003) Age-dependent cerebrovascular abnormalities and blood flow disturbances in APP23 mice modeling Alzheimer’s disease. J Neurosci 23:8453–8459

  5. Belliveau JW, Rosen BR, Kantor HL, Rzedzian RR, Kennedy DN, McKinstry RC, Vevea JM, Cohen MS, Pykett IL, Brady TJ (1990) Functional cerebral imaging by susceptibility-contrast NMR. Magn Reson Med 14:538–546

  6. Boxerman JL, Hamberg LM, Rosen BR, Weisskoff RM (1995) MR contrast due to intravascular magnetic susceptibility perturbations. Magn Reson Med 34:555–566

  7. Breteler MM (2000) Vascular risk factors for Alzheimer’s disease: an epidemiologic perspective. Neurobiol Aging 21:153–160

  8. Choeiri C, Staines W, Messier C (2002) Immunohistochemical localization and quantification of glucose transporters in the mouse brain. Neuroscience 111:19–34

  9. de la Torre JC (2000a) Impaired cerebromicrovascular perfusion. Summary of evidence in support of its causality in Alzheimer’s disease. Ann NY Acad Sci 924:136–152

  10. de la Torre JC (2000b) Cerebral hypoperfusion, capillary degeneration, and development of Alzheimer disease. Alzheimer Dis Assoc Disord 14(Suppl 1):S72–S81

  11. de la Torre JC (2000c) Critically attained threshold of cerebral hypoperfusion: the CATCH hypothesis of Alzheimer’s pathogenesis. Neurobiol Aging 21:331–342

  12. de la Torre JC (2002) Alzheimer disease as a vascular disorder: nosological evidence. Stroke 33:1152–1162

  13. de la Torre JC (2004) Is Alzheimer’s disease a neurodegenerative or a vascular disorder? Data, dogma, and dialectics. Lancet Neurol 3:184–190

  14. de la Torre JC, Stefano GB (2000) Evidence that Alzheimer’s disease is a microvascular disorder: the role of constitutive nitric oxide. Brain Res Brain Res Rev 34:119–136

  15. Dennie J, Mandeville JB, Boxerman JL, Packard SD, Rosen BR, Weisskoff RM (1998) NMR imaging of changes in vascular morphology due to tumor angiogenesis. Magn Reson Med 40:793–799

  16. Dorr A, Sled JG, Kabani N (2007) Three-dimensional cerebral vasculature of the CBA mouse brain: a magnetic resonance imaging and micro computed tomography study. NeuroImage 35:1409–1423

  17. El Tayara Nel T, Delatour B, Volk A, Dhenain M (2010) Detection of vascular alterations by in vivo magnetic resonance angiography and histology in APP/PS1 mouse model of Alzheimer’s disease. MAGMA 23:53–64

  18. Franklin KBJ, Paxinos G (1997) The mouse brain in stereotaxic coordinates. Academic Press, San Diego

  19. Garcia-Alloza M, Robbins EM, Zhang-Nunes SX, Purcell SM, Betensky RA, Raju S, Prada C, Greenberg SM, Bacskai BJ, Frosch MP (2006) Characterization of amyloid deposition in the APPswe/PS1dE9 mouse model of Alzheimer disease. Neurobiol Dis 24:516–524

  20. Ghiso J, Frangione B (2002) Amyloidosis and Alzheimer’s disease. Adv Drug Deliv Rev 54:1539–1551

  21. Grammas P (2000) A damaged microcirculation contributes to neuronal cell death in Alzheimer’s disease. Neurobiol Aging 21:199–205

  22. Haass C, Selkoe DJ (2007) Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer’s amyloid β-peptide. Nat Rev Mol Cell Biol 8:101–112

  23. Hansen TD, Warner DS, Todd MM, Vust LJ (1989) Effects of nitrous oxide and volatile anaesthetics on cerebral blood flow. Br J Anaesth 63:290–295

  24. Hao W, Liu Y, Liu S, Walter S, Grimm MO, Kiliaan AJ, Penke B, Hartmann T, Rube CE, Menger MD, Fassbender K (2011) Myeloid differentiation factor 88-deficient bone marrow cells improve Alzheimer’s disease-related symptoms and pathology. Brain 134:278–292

  25. Helzner EP, Luchsinger JA, Scarmeas N, Cosentino S, Brickman AM, Glymour MM, Stern Y (2009) Contribution of vascular risk factors to the progression in Alzheimer disease. Arch Neurol 66:343–348

  26. Hooijmans CR, Rutters F, Dederen PJ, Gambarota G, Veltien A, van Groen T, Broersen LM, Lütjohann D, Heerschap A, Tanila H, Kiliaan AJ (2007a) Changes in cerebral blood volume and amyloid pathology in aged Alzheimer APP/PS1 mice on a docosahexaenoic acid (DHA) diet or cholesterol enriched typical Western diet (TWD). Neurobiol Dis 28:16–29

  27. Hooijmans CR, Graven C, Dederen PJ, Tanila H, van Groen T, Kiliaan AJ (2007b) Amyloid beta deposition is related to decreased glucose transporter-1 levels and hippocampal atrophy in brains of aged APP/PS1 mice. Brain Res 1181:93–103

  28. Hooijmans CR, Van der Zee CE, Dederen PJ, Brouwer KM, Reijmer YD, van Groen T, Broersen LM, Lutjohann D, Heerschap A, Kiliaan AJ (2009) DHA and cholesterol containing diets influence Alzheimer-like pathology, cognition and cerebral vasculature in APPswe/PS1dE9 mice. Neurobiol Dis 33:482–498

  29. Iadecola C (2004) Neurovascular regulation in the normal brain and in Alzheimer’s disease. Nat Rev Neurosci 5:347–360

  30. Iadecola C (2010) The overlap between neurodegenerative and vascular factors in the pathogenesis of dementia. Acta Neuropathol 120:287–296

  31. Iadecola C, Zhang F, Niwa K, Eckman C, Turner SK, Fischer E, Younkin S, Borchelt DR, Hsiao KK, Carlson GA (1999) SOD1 rescues cerebral endothelial dysfunction in mice overexpressing amyloid precursor protein. Nat Neurosci 2:157–161

  32. Jankowsky JL, Slunt HH, Ratovitski T, Jenkins NA, Copeland NG, Borchelt DR (2001) Co-expression of multiple transgenes in mouse CNS: a comparison of strategies. Biomol Eng 17:157–165

  33. Jankowsky JL, Slunt HH, Gonzales V, Jenkins NA, Copeland NG, Borchelt DR (2004) APP processing and amyloid deposition in mice haplo-insufficient for presenilin 1. Neurobiol Aging 25:885–892

  34. Kalaria R (2002) Similarities between Alzheimer’s disease and vascular dementia. J Neurol Sci 203–204:29–34

  35. Kamenetz F, Tomita T, Hsieh H, Seabrook G, Borchelt D, Iwatsubo T, Sisodia S, Malinow R (2003) APP processing and synaptic function. Neuron 37:925–937

  36. Krucker T, Schuler A, Meyer EP, Staufenbiel M, Beckmann N (2004) Magnetic resonance angiography and vascular corrosion casting as tools in biomedical research: application to transgenic mice modeling Alzheimer’s disease. Neurol Res 26:507–516

  37. Larson ME, Lesne SE (2012) Soluble Aβ oligomer production and toxicity. J Neurochem 120(Suppl 1):125–139

  38. Le Duc G, Peoc’h M, Remy C, Charpy O, Muller RN, Le Bas JF, Decorps M (1999) Use of T(2)-weighted susceptibility contrast MRI for mapping the blood volume in the glioma-bearing rat brain. Magn Reson Med 42:754–761

  39. Liu Y, Yoo MJ, Savonenko A, Stirling W, Price DL, Borchelt DR, Mamounas L, Lyons WE, Blue ME, Lee MK (2008) Amyloid pathology is associated with progressive monoaminergic neurodegeneration in a transgenic mouse model of Alzheimer’s disease. J Neurosci 28:13805–13814

  40. Lue LF, Kuo YM, Roher AE, Brachova L, Shen Y, Sue L, Beach T, Kurth JH, Rydel RE, Rogers J (1999) Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer’s disease. Am J Pathol 155:853–862

  41. Maier M, Peng Y, Jiang L, Seabrook TJ, Carroll MC, Lemere CA (2008) Complement C3 deficiency leads to accelerated amyloid beta plaque deposition and neurodegeneration and modulation of the microglia/macrophage phenotype in amyloid precursor protein transgenic mice. J Neurosci 28:6333–6341

  42. McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, Beyreuther K, Bush AI, Masters CL (1999) Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimer’s disease. Ann Neurol 46:860–866

  43. Meyer JS, Rauch GM, Rauch RA, Haque A, Crawford K (2000) Cardiovascular and other risk factors for Alzheimer’s disease and vascular dementia. Ann NY Acad Sci 903:411–423

  44. Meyer EP, Ulmann-Schuler A, Staufenbiel M, Krucker T (2008) Altered morphology and 3D architecture of brain vasculature in a mouse model for Alzheimer’s disease. Proc Natl Acad Sci USA 105:3587–3592

  45. Niwa K, Carlson GA, Iadecola C (2000) Exogenous Aβ1-40 reproduces cerebrovascular alterations resulting from amyloid precursor protein overexpression in mice. J Cereb Blood Flow Metab 20:1659–1668

  46. Niwa K, Kazama K, Younkin L, Younkin SG, Carlson GA, Iadecola C (2002a) Cerebrovascular autoregulation is profoundly impaired in mice overexpressing amyloid precursor protein. Am J Physiol Heart Circ Physiol 283:H315–H323

  47. Niwa K, Kazama K, Younkin SG, Carlson GA, Iadecola C (2002b) Alterations in cerebral blood flow and glucose utilization in mice overexpressing the amyloid precursor protein. Neurobiol Dis 9:61–68

  48. Peppiatt CM, Howarth C, Mobbs P, Attwell D (2006) Bidirectional control of CNS capillary diameter by pericytes. Nature 443:700–704

  49. Sawiak SJ, Wood NI, Williams GB, Morton AJ, Carpenter TA (2009) Voxel-based morphometry in the R6/2 transgenic mouse reveals differences between genotypes not seen with manual 2D morphometry. Neurobiol Dis 33:20–27

  50. Skoog I, Gustafson D (2002) Hypertension and related factors in the etiology of Alzheimer’s disease. Ann NY Acad Sci 977:29–36

  51. Tropres I, Grimault S, Vaeth A, Grillon E, Julien C, Payen JF, Lamalle L, Decorps M (2001) Vessel size imaging. Magn Reson Med 45:397–408

  52. Walsh DM, Selkoe DJ (2007) Aβ oligomers—a decade of discovery. J Neurochem 101:1172–1184

  53. Weidensteiner C, Metzger F, Bruns A, Bohrmann B, Kuennecke B, von Kienlin M (2009) Cortical hypoperfusion in the B6.PS2APP mouse model for Alzheimer’s disease: comprehensive phenotyping of vascular and tissular parameters by MRI. Magn Reson Med 62:35–45

  54. Weiss HR, Buchweitz E, Murtha TJ, Auletta M (1982) Quantitative regional determination of morphometric indices of the total and perfused capillary network in the rat brain. Circ Res 51:494–503

  55. Wu EX, Wong KK, Andrassy M, Tang H (2003) High-resolution in vivo CBV mapping with MRI in wild-type mice. Magnetic Reson Med 49:765–770

  56. Wu EX, Tang H, Asai T, Yan SD (2004) Regional cerebral blood volume reduction in transgenic mutant APP (V717F, K670N/M671L) mice. Neurosci Lett 365:223–227

  57. Zlokovic BV (2008) The blood–brain barrier in health and chronic neurodegenerative disorders. Neuron 57:178–201

  58. Zlokovic BV (2011) Neurovascular pathways to neurodegeneration in Alzheimer’s disease and other disorders. Nat Rev Neurosci 12:723–738

Download references

Acknowledgments

The author acknowledges Dr. Giulio Gambarota, Dr. Carmen Capone, Carola Janssen, Michiel Kleinnijenhuis and Xiaotian Fang for their technical and scientific assistance in writing this manuscript. The research leading to these results has received funding from the EU FP7 project LipiDiDiet, Grant Agreement No 211696 and was supported by NWO investment grants nr 91106021 and BIG (VISTA).

Conflict of interest

There are no actual or potential conflicts of interest to report for any of the authors.

Author information

Correspondence to Amanda J. Kiliaan.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Video 1. Representative 3D reconstruction of macrovasculature rCBVmacro mask in three-dimensional view identifies the major surrounding and perforating brain arteries and vein

Supplementary material 1 (MPEG 3934 kb)

Supplementary material 1 (MPEG 3934 kb)

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Zerbi, V., Jansen, D., Dederen, P.J. et al. Microvascular cerebral blood volume changes in aging APPswe/PS1dE9 AD mouse model: a voxel-wise approach. Brain Struct Funct 218, 1085–1098 (2013) doi:10.1007/s00429-012-0448-8

Download citation

Keywords

  • Alzheimer’s disease
  • APP/PS1 mice
  • Cerebral blood volume
  • Amyloid-β
  • Voxel-wise analysis